Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06764485 | A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | PHASE3 | RECRUITING | 960 | — | — | Mar 13, 2025 | Jan 19, 2029 | May 6, 2026 | 282 | United States, Argentina +24 |
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose 1 | EXPERIMENTAL | - |
| Part 1: Dose 2 | EXPERIMENTAL | - |
| Part 1: Comparator 1 | ACTIVE_COMPARATOR | Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone |
| Part 1: Comparator 2 | ACTIVE_COMPARATOR | - |
| Part 2: Dose Selected | EXPERIMENTAL | - |
| Part 2: Comparator 1 | ACTIVE_COMPARATOR | Enzalutamide or Abiraterone Acetate + Prednisone/Prednisolone |
| Part 2: Comparator 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| BMS-986365 | DRUG | Specified dose on specified days |
| Enzalutamide | DRUG | Specified dose on specified days |
| Abiraterone | DRUG | Specified dose on specified days |
| Docetaxel | DRUG | Specified dose on specified days |
| Predinsone/Prednisolone | DRUG | Specified dose on specified days |
Inclusion Criteria * Participants must have histologic or cytologic confirmation of adenocarcinoma of the prostate without small cell or neuro-endocrine features. * Participants must have current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft ...